Outcome-Based Pricing in MedTech: Can You Prove the Value You’re Pricing?
Outcome-based pricing only works when medtech companies can define a meaningful outcome, measure it consistently, connect it to the product, and support the commercial and data infrastructure behind the agreement.
In this article:
The Device Price Is Only Part of the Value
First, Define the Outcome
Can You Prove the Device Contributed to It?
The Data Has to Hold Up
Someone Has to Own the Risk
How This Looks Across Our Three MedTech Segments
An Outcome-Based Pricing Readiness Check
Outcome-Based Pricing Only Works If the Proof Is There
Ilike the idea of outcome-based pricing.
On paper, it makes a lot of sense. If a medical technology helps deliver a better result, why shouldn’t some part of the price reflect that value?
The problem is that the conversation gets complicated pretty quickly.
What result are we actually talking about? Fewer complications? Lower readmissions? Better adherence? Shorter procedure time? Lower total cost of care?
Then comes the harder question: how much of that result came from the device?
A patient outcome is rarely influenced by one thing. The clinician, the care team, the patient, other therapies, hospital processes, and even whether the technology was used as intended can all affect the result.
That does not make outcome-based pricing a bad idea. I think it means medtech companies need to be much more thoughtful about where they use it.
The strongest opportunities are the ones where the product has a clear connection to the result and where both sides can agree on how that result will be measured.
That requires more than a new pricing model. You need good data, a baseline everyone trusts, clear definitions, and agreement on what happens when outside factors affect the outcome.
If you can do that well, the conversation with providers and payers becomes much more interesting. You are no longer just talking about what the product costs. You are talking about what it actually delivers.
But if you cannot prove the value clearly, outcome-based pricing can turn into a very complicated contract around a number nobody fully agrees with.
The Device Price Is Only Part of the Value
One thing I think medtech companies sometimes underestimate is how differently the customer may define value.
The manufacturer may be focused on product performance, features, and clinical evidence. The provider may be asking a broader question: what does this help us improve?
That could be procedure time, staffing, readmissions, patient adherence, equipment utilization, complications, recovery time, or total cost of care.
A surgical system, for example, may cost more upfront but reduce procedure time or simplify setup. A wearable may create value by helping a care team intervene earlier. A software-based device may help clinicians review cases faster or focus attention on the patients who need it most.
Those benefits can be harder to see than the product price, but they may be far more important to the customer. But instead of defending the cost of the technology, the company can talk about the result it helps create.
But you have to be careful not to overreach. If the value depends on several other things going right, say that. If the benefit only shows up with a certain patient population or workflow, account for it. If the customer has to change how they operate to get the result, that belongs in the conversation too.
The goal should be to understand which outcomes the customer actually cares about and whether your product has a credible role in improving them. Don’t attach a dollar amount to every possible benefit.
Once you know that, the pricing discussion gets a lot more useful.
First, Define the Outcome
Before you can price around an outcome, you have to be very specific about what that outcome is.
“Better patient outcomes” is not enough. Neither is “improved efficiency.”
You need something both sides can actually measure and agree on.
For one product, that may be a reduction in readmissions within 30 days. For another, it could be procedure time, complication rates, adherence, equipment uptime, or the number of patients who require an in-person follow-up.
The definition can get tricky fast.
Take readmissions. Are you counting all readmissions, or only the ones related to the condition the device is treating? What if the patient has other health issues? What if they did not use the device as directed? And how long after treatment are you still tying that outcome back to the product?
The same issue comes up with operational outcomes.
If a surgical system is supposed to reduce procedure time, what is the baseline? Is it compared against the same surgeon, the same type of case, or the hospital average? If staffing changes halfway through the contract, does that affect the measurement?
These details may sound overly specific, but they are exactly where disagreements start later.
Both sides need to know what success looks like before the contract begins. That includes the metric, the baseline, the measurement period, the data source, and any situations that should be excluded.
If you cannot define the outcome clearly, you probably are not ready to price against it.
Can You Prove the Device Contributed to It?
Defining the outcome is one thing. Proving your product helped create it is another.
A medical device rarely operates in isolation. The clinician’s decisions, the patient’s behavior, other therapies, hospital processes, and even staffing can all influence the result.
So if outcomes improve, how much credit should the product get?
For a wearable, maybe the device helped identify a problem earlier. But did the patient respond to the alert? Did the care team act on it quickly? Was another intervention what really changed the outcome?
For a surgical system, procedure time may improve after adoption. But was that because of the technology, the surgeon’s experience, a new workflow, or all three?
The same issue shows up with software-based devices. A tool may help prioritize cases or support a clinical decision, but the final outcome still depends on what someone does with that information.
You do not need to prove the device caused 100% of the result. In most cases, that would not be realistic.
You do need enough evidence to show that the product had a meaningful and measurable role. That may mean agreeing on a control group, historical baseline, patient population, utilization threshold, or other way to compare performance fairly.
It also means being honest about the things outside your control. If the customer expects the device to deliver an outcome but the result depends heavily on adoption, training, workflow changes, or patient participation, those dependencies should be part of the commercial discussion from the beginning.
The more complicated the care pathway, the more careful you have to be about claiming credit for the result.
The Data Has to Hold Up
Outcome-based pricing falls apart pretty quickly if both sides are working from different numbers.
You need to know where the data comes from, how complete it is, and whether everyone trusts it enough to use it in a commercial agreement.
That can be harder than it sounds.
The outcome may depend on data from the device, the hospital, the patient, a CRM, an EHR, or another system entirely. Those sources may not match perfectly. They may use different definitions, timestamps, patient identifiers, or reporting methods.
For a wearable, for example, you may have great device data but gaps in patient adherence or follow-up. For a surgical system, procedure data may be available, but not in a format that makes comparison easy across sites. With a software-based device, the product may capture usage and recommendations, while the actual clinical outcome lives somewhere else.
Before tying money to any of it, both sides should agree on the source of truth.
That includes questions like:
I would also be careful about building an outcome-based model around data that requires a lot of manual cleanup every month.
If the commercial agreement depends on a spreadsheet somebody has to reconcile by hand, it is going to be hard to scale.
The better the data foundation, the easier it is to have a fair conversation about value.
Someone Has to Own the Risk
Outcome-based pricing changes more than how a medtech company gets paid – it changes who carries the risk when the expected result does not happen.
If a medical device manufacturer agrees to tie part of the price to a clinical or operational outcome, what happens when the product performs as expected but the customer does not follow the recommended workflow? What if adoption is low? What if the patient population is more complex than expected? What if the provider changes staffing, protocols, or supporting technology halfway through the agreement?
For a wearable, the manufacturer may be comfortable standing behind device performance, but not patient adherence. For a surgical system, the company may be willing to share risk around uptime or procedure efficiency, but not take responsibility for every factor that affects a surgical outcome. For a software-based medical device, the product may surface the right information and still depend on a clinician to act on it.
This is why the contract needs to separate what the medtech company can control from what it cannot.
That may include agreed thresholds for product use, training, patient participation, workflow compliance, or data availability. It may also mean putting limits around how much financial risk either side takes on.
I would be cautious about arrangements where the medical device manufacturer is effectively being asked to guarantee an outcome it only partially influences.
Shared risk can make sense. Undefined risk usually does not.
The strongest agreements give both sides some skin in the game, but they also spell out the conditions needed for the model to work.
If those conditions are vague, the commercial relationship can get uncomfortable very quickly.
How This Looks Across Our Three MedTech Segments
Outcome-based pricing will not look the same across every medtech category.
For For Agentic and Software as a Medical Device. the value may come from helping clinicians make decisions faster, prioritize cases, reduce manual review, or intervene earlier. The hard part is separating the value of the software from the actions that happen after it delivers an insight.
For For smart implants and wearables, the connection to outcomes can be more direct. Medical device manufacturers may be able to tie value to adherence, earlier detection, reduced complications, fewer in-person visits, or better management of chronic conditions. But patient participation and care-team response still play a big role.
For surgical equipment, outcome-based models may focus more on procedure efficiency, uptime, throughput, complication reduction, or total cost per case. In some situations, the commercial model may blend clinical and operational measures rather than rely on one outcome alone.
A medtech company may have one product where the value is clearly clinical, another where it is mostly operational, and a third where the customer cares about both.
Trying to force every product into the same definition of value will create more confusion than progress. The better approach is to start with the result the customer actually cares about, then decide whether the product has a strong enough connection to that result to support an outcome-based agreement.
An Outcome-Based Pricing Readiness Check
Before a medtech company ties pricing to performance, I would look at five things.
If one of these areas is weak, the pricing model usually gets harder to manage very quickly.
I would not treat this as a checklist for deciding whether outcome-based pricing is “good” or “bad.” It is really a way to decide whether a particular product, customer, and use case are ready for it.
Outcome-Based Pricing Only Works If the Proof Is There
I think outcome-based pricing has a lot of promise for medtech, but only when the fundamentals are there.
You need a clear outcome. You need data both sides trust. You need a reasonable way to show that the product contributed to the result. And you need to be very specific about who owns which part of the risk.
If those pieces are missing, the pricing model gets complicated fast.
For medical device manufacturers, the opportunity is not just to charge differently. It is to have a better conversation about value.
Instead of focusing only on what the product costs, you can show what it helps improve and why that improvement is worth paying for.
That is a stronger position, but only if you can prove it.
Next in the Series: Cybersecurity by Design
The next trend is one medtech companies cannot afford to treat as a late-stage compliance exercise.
As devices become more connected, software-driven, and dependent on cloud platforms and data, cybersecurity has to be built into the product from the start.
In the next article, I’ll look at what Cybersecurity by Design really means for medical device manufacturers, and why security decisions now affect product architecture, regulatory strategy, validation, service, and the full product lifecycle.
